Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective
References (36)
- et al.
for the Cholesterol Treatment Trialists' (CTT) Collaborators
Efficacy and safety of cholesterollowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [published correction appears in Lancet. 2005;366: 1358]. Lancet
(2005) - et al.
Recommendations for the management and treatment of dyslipidemia: Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias
CMAJ
(2000) PPS Buyers Guide
(2007)- et al.
Safety of rosuvastatin: Update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program
Cardiology
(2007) - et al.
Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease [published correction appears in J Intern Med
2006;260:186]. J Intern Med
(2006) - et al.
Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease
EurJClin Pharmacol
(2005) - et al.
An evaluation of the factors associated with statin dose management and low-density lipoprotein-cholesterol goal attainment
Dis Manag Health Outcomes
(2006) - et al.
A method for comparing and combining cost-of-illness studies: An example from cardiovascular disease
Chronic Dis Can
(2002) - Age-standardized mortality rates by selected causes, by sex [Statistics Canada Web...
- et al.
Canadian Cardiovascular Society position statement—Recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease
Can J Cardiol
(2006)
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report
Circulation
for the Latin American Group
The importance of low serum levels of high-density lipoprotein cholesterol (HDL-C) as a cardiovascular risk factor. Diab Vasc Dis Res
Hypertriglyceridemia: Its etiology, effects and treatment
CMAJ
New risk factors for atherosclerosis and patient risk assessment
Circulation
the apolipoprotein B/AI ratio and coronary heart disease: A literature-based metaanalysis of prospective studies
J Intern Med
The apoB/apoA-I ratio: A strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy—a review of the evidence
J Intern Med
Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease
J Intern Med
Cited by (15)
Simultaneous quantification of simvastatin and simvastatin hydroxy acid in blood serum at physiological pH by ultrahigh performance liquid chromatography-tandem mass spectrometry (UHPLC/MS/MS)
2014, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesCitation Excerpt :Statins are prescribed to treat hypercholesterolemia or high cholesterol. In 2007, Canadian statin sales totalled $1.6 billion, placing them among the most prescribed pharmaceuticals [1]. Statins function by reducing both total and low-density lipoprotein (LDL) cholesterol [2].
Evidence-based prediction of statin use with lipid-panel data from the national health and nutrition examination survey
2012, Value in HealthCitation Excerpt :However, due to the absence of similar studies for the other statins, the evidence does not support superiority with respect to these various endpoints. Cost-effectiveness studies, again primarily sponsored by the market leaders, suggest that the leading statins have good value [37–39], although, again, they do not show that the other statins do not. Finally, at the writing of this article, three of the statins are available as generics (lovastatin since the end of 2001, and pravastatin and simvastatin since 2006), whereas the others are not.
Statintherapy in the primary and the secondary prevention of ischaemic cerebrovascular diseases
2011, International Journal of CardiologyCitation Excerpt :A recent study study assessed 12,041 patients found that rosuvastatin patients who attained the NCEP ATP III target LDL-C goal had significantly lower titration rates than patients receiving other statins [24]. When percent changes in lipid parameters and rates of LDL-C goal attainment were considered in patients with hypercholesterolemia in British Columbia, rosuvastatin 10 mg was more cost-effective than the most frequently used doses of atorvastatin (10 and 20 mg), generic simvastatin (20 and 40 mg), and generic pravastatin (20 and 40 mg) [26]. These results had been confirmed by another analysis which provided evidence (data were extracted from the STELLAR trial) that prescribing generic statins in Canada does not necessarily translated into the most cost-effective option for treating dyslipidemia; especially as the monetary value of 1% decrease in LDL-C or patients achieving NCEP ATP III target increases.
Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
2012, ClinicoEconomics and Outcomes ResearchModel-based cost-effectiveness analysis of atorvastatin drugs for prevention of cardiovascular diseases in Iran
2020, International Journal of Preventive MedicineAnalysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea
2017, Journal of Clinical Pharmacy and Therapeutics